References

n.d.

Al Malki, Monzr M., Alla Keyzner, Hyung C. Suh, et al. 2024. “A Phase 1 Trial of TSC-100 and TSC-101, Engineered t Cell Therapies That Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation.” Journal of Clinical Oncology 42 (16_suppl): TPS2678–78. https://doi.org/10.1200/jco.2024.42.16_suppl.tps2678.

Arellano, Martha L., Michael J. Thirman, John F. DiPersio, et al. 2025. “Menin Inhibition with Revumenib for NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study.” Blood Journal, ahead of print, May 7. https://doi.org/10.1182/blood.2025028357.

Cull, Elizabeth H., Justin M. Watts, Martin S. Tallman, et al. 2014. “Acute Myeloid Leukemia Presenting with Panhypopituitarism or Diabetes Insipidus: A Case Series with Molecular Genetic Analysis and Review of the Literature.” Leukemia & Lymphoma 55 (9): 2125–29. https://doi.org/10.3109/10428194.2013.869327.

DiNardo, Courtney D., Wei-Ying Jen, Koichi Takahashi, et al. 2025. “Long Term Results of Venetoclax Combined with FLAG-IDA Induction and Consolidation for Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.” Leukemia 39 (4): 854–63. https://doi.org/10.1038/s41375-025-02531-8.

Fathi, Amir T., Aleksandra Filipovic, Keri Maher, et al. 2024. “A Phase i Dose Escalation and Expansion Trial of Lyt-200 (a First-in-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS.” Blood 144 (Supplement 1): 1499–99. https://doi.org/10.1182/blood-2024-209848.

Hunault, Mathilde, Cécile Pautas, Sarah Bertoli, et al. 2025. “Intermediate-Dose Cytarabine as Postinduction AML Therapy.” NEJM Evidence 4 (7). https://doi.org/10.1056/evidoa2400326.

Issa, Ghayas C., Ibrahim Aldoss, John DiPersio, et al. 2023. “The Menin Inhibitor Revumenib in KMT2A-Rearranged or NPM1-Mutant Leukaemia.” Nature 615 (7954): 920–24. https://doi.org/10.1038/s41586-023-05812-3.

Issa, Ghayas C., Ibrahim Aldoss, Michael J. Thirman, et al. 2025. “Menin Inhibition with Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).” Journal of Clinical Oncology 43 (1): 75–84. https://doi.org/10.1200/jco.24.00826.

Issa, Ghayas C., Aram Bidikian, Sangeetha Venugopal, et al. 2023. “Clinical Outcomes Associated with NPM1 Mutations in Patients with Relapsed or Refractory AML.” Blood Advances 7 (6): 933–42. https://doi.org/10.1182/bloodadvances.2022008316.

Issa, Ghayas C., Eytan M. Stein, and Courtney D. DiNardo. 2025. “How i Treat Acute Myeloid Leukemia with Differentiation Therapy.” Blood 145 (12): 1251–59. https://doi.org/10.1182/blood.2024024008.

Issa, Ghayas C., Jabra Zarka, Koji Sasaki, et al. 2021. “Predictors of Outcomes in Adults with Acute Myeloid Leukemia and KMT2A Rearrangements.” Blood Cancer Journal 11 (9). https://doi.org/10.1038/s41408-021-00557-6.

Knuth, Donald E. 1984. “Literate Programming.” Comput. J. (USA) 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.

Merz, Lauren E., Anthony J. Perissinotti, Bernard L. Marini, et al. 2020. “Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia with Recurrent Genetic AbnormalitiesAML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.” Clinical Lymphoma Myeloma and Leukemia 20 (1): 24–30. https://doi.org/10.1016/j.clml.2019.09.615.

Pullarkat, Vinod, Keith W. Pratz, Hartmut Döhner, et al. 2025. “Venetoclax and Azacitidine in Untreated Patients with Therapy-Related Acute Myeloid Leukemia, Antecedent Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia.” Blood Cancer Journal 15 (1). https://doi.org/10.1038/s41408-025-01263-3.

Wang, Eunice S, Ghayas C Issa, Harry P Erba, et al. 2024. “Ziftomenib in Relapsed or Refractory Acute Myeloid Leukaemia (KOMET-001): A Multicentre, Open-Label, Multi-Cohort, Phase 1 Trial.” The Lancet Oncology 25 (10): 1310–24. https://doi.org/10.1016/s1470-2045(24)00386-3.

Willekens, Christophe, Alexandre Bazinet, Samy Chraibi, et al. 2025. “Reduced Venetoclax Exposure to 7 Days Vs Standard Exposure with Hypomethylating Agents in Newly Diagnosed AML Patients.” Blood Cancer Journal 15 (1). https://doi.org/10.1038/s41408-025-01269-x.